| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 07/16/2002 | US6420126 Tumor specific internalizing antigens and methods for targeting therapeutic agents |
| 07/16/2002 | US6419963 Composition and method for the treatment of diaper rash using natural products |
| 07/16/2002 | US6419901 Anticancer agents |
| 07/16/2002 | US6419900 Formulation and method for treating neoplasms by inhalation |
| 07/16/2002 | CA2214097C Use of ketorolac for treatment of squamous cell carcinomas of the oral cavity or oropharynx |
| 07/16/2002 | CA2165518C P substance antagonist used for the treatment of neurogenous skin redness |
| 07/16/2002 | CA2125666C Medicaments |
| 07/16/2002 | CA1341377C Composition and method for acceleration of clot lysis |
| 07/11/2002 | WO2002054073A2 Latent human tuberculosis model, diagnostic antigens, and methods of use |
| 07/11/2002 | WO2002054072A2 Assay to determine efficacy of treatment for mycobacterial infection |
| 07/11/2002 | WO2002054064A2 Method for screening for progesterone receptor isoform-specific ligands |
| 07/11/2002 | WO2002053743A2 Mammalian tribbles signaling pathways and methods and reagents related thereto |
| 07/11/2002 | WO2002053740A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 07/11/2002 | WO2002053733A2 Regulation of human b7-h2 protein |
| 07/11/2002 | WO2002053728A2 Gene disruption methodologies for drug target discovery |
| 07/11/2002 | WO2002053717A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 07/11/2002 | WO2002053711A2 Use of transcription factor yb-1 in adenoviral systems |
| 07/11/2002 | WO2002053596A2 Antibodies to insulin-like growth factor i receptor |
| 07/11/2002 | WO2002053594A2 Inhibitors of memapsin 2 and use thereof |
| 07/11/2002 | WO2002053580A2 Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs |
| 07/11/2002 | WO2002053564A2 Quinuclidine derivatives and their use as m3 antagonists |
| 07/11/2002 | WO2002053187A2 Methods and transdermal compositions for pain relief |
| 07/11/2002 | WO2002053185A2 Anti-inflammatory use of polycationic compounds |
| 07/11/2002 | WO2002053177A2 Agents and methods for treating pain |
| 07/11/2002 | WO2002053171A2 Use of intermediate-conductance potassium channels and modulators for the diagnosis and treatment of illnesses having disturbed keratinocyte activity |
| 07/11/2002 | WO2002053170A2 Combined use of enzyme inhibitors and pharmaceutical preparations thereof for the treatment and prophylaxis of arteriosclerosis, for the treatment and prevention of allergic reactions of type i according to the gell and coombs classification, and for the treatment and prevention of dermatological diseases associated with fo |
| 07/11/2002 | WO2002053158A1 Method for treating glaucoma ib |
| 07/11/2002 | WO2002053151A1 Perfume compositions |
| 07/11/2002 | WO2002053143A2 Treatment of erectile dysfunction with rho-kinase inhibitors |
| 07/11/2002 | WO2002053142A2 Compositions and methods for enhancing cytokine activity and treating hypotension associated with the administration of cytokines |
| 07/11/2002 | WO2002053141A2 Inhibition of angiogenesis by nucleic acids |
| 07/11/2002 | WO2002053140A2 New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents |
| 07/11/2002 | WO2002053138A2 Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens |
| 07/11/2002 | WO2002053137A2 Pharmaceutical composition for treatment of phimosis using topical corticosteroid |
| 07/11/2002 | WO2002053127A1 Agents for inhibiting or restoring skin damage caused by drying and method of evaluating the same |
| 07/11/2002 | WO2002053110A2 Pharmaceutical preparation for douches and/or irrigations of natural or pathological cavities in the human body |
| 07/11/2002 | WO2002053100A2 Pharmaceutical dosage form for oral administration of low molecular weight heparin |
| 07/11/2002 | WO2002053099A2 Methods and compositions for treating periodontal disease |
| 07/11/2002 | WO2002053097A2 Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination |
| 07/11/2002 | WO2002053096A2 Single therapy and combination therapy involving drugs with target cellular proteins and drugs which target pathogen-encoded proteins |
| 07/11/2002 | WO2002053092A2 Methods employing and compositions containing plaque associated molecules for prevention and treatment of atherosclerosis |
| 07/11/2002 | WO2002053089A2 Stable skin conditioning compositions containing retinoid boosters |
| 07/11/2002 | WO2002052957A1 Creatine/citric acid compound, method for the production of the same and the use thereof |
| 07/11/2002 | WO2002052955A1 Nutritional and therapeutical preparations having antioxidant activity |
| 07/11/2002 | WO2002052934A2 Pesticidal and antiparasitic compositions |
| 07/11/2002 | WO2002041918A3 Use of a triple combination comprising a 5ht3 antagonist, a 5ht4 agonist and a laxative for promoting intestinal lavage |
| 07/11/2002 | WO2002034119A3 Vaccine immunotherapy for immune suppressed patients |
| 07/11/2002 | WO2002030410A3 Suppression of cyclin kinase activity for prevention and treatment of infections |
| 07/11/2002 | WO2002028349A3 Method of treating cancer using dithiocarbamate derivatives |
| 07/11/2002 | WO2002024632A3 Substituted aminopropoxyaryl derivatives useful as agonists for lxr |
| 07/11/2002 | WO2002020724A3 Adenoviral targeting and manipulation of immune system response using targeting peptides |
| 07/11/2002 | WO2002020022B1 Method of treating neurologic disorders |
| 07/11/2002 | WO2002017831A3 Devices for intraocular drug delivery |
| 07/11/2002 | WO2002014511A3 Regulation of human p2y1-like g protein-coupled receptor |
| 07/11/2002 | WO2002011716A3 Liquid formulation of metformin |
| 07/11/2002 | WO2002011666A3 Derivatives of branched-chain lipophilic molecules and uses thereof |
| 07/11/2002 | WO2002008456A8 Method for identifying metastatic tumor cells |
| 07/11/2002 | WO2001091783A3 Methods and compositions for producing a neurosalutary effect in a subject |
| 07/11/2002 | WO2001090747A3 Modulation of t-cell receptor interactions |
| 07/11/2002 | WO2001081412A3 Isolated human transporter proteins, nucleic acid molecules encoding the same, and uses thereof |
| 07/11/2002 | WO2001080896A3 Flavopiridol drug combinations and methods with reduced side effects |
| 07/11/2002 | WO2001074389A3 Improved treatment of neovascularization |
| 07/11/2002 | WO2001049300A3 Combinations for the treatment of dna viral infections comprising a loop diuretic and lithium |
| 07/11/2002 | WO2001049242A3 Combinations for the treatment of dna viral infections comprising a loop diuretic cardiac glycoside |
| 07/11/2002 | WO2001046443A3 Proteases |
| 07/11/2002 | WO2001046383A9 Compositions and methods involving an essential staphylococcus aureus gene and its encoded protein |
| 07/11/2002 | WO2001044473A3 Polypeptides and nucleic acids encoding same |
| 07/11/2002 | WO2001039763A3 Use of methylol-containing compounds for the manufacture of a medicament for the treatment of tumors |
| 07/11/2002 | WO2001034225A3 Hyperoncotic artificial cerebrospinal fluid and method of treating neural tissue edema therewith |
| 07/11/2002 | WO2001034205A3 Use of lytic toxins and toxin conjugates |
| 07/11/2002 | WO2001031580A3 Methods and devices for identifying patterns in biological systems |
| 07/11/2002 | WO2001030392A3 Delivery of proteins across polar epithelial cell layers |
| 07/11/2002 | WO2001029054A3 Medicaments for treatment of respiratory syncytial virus infections |
| 07/11/2002 | WO2001024785A3 Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases |
| 07/11/2002 | WO2001021213A3 Inhibition of secretion from non-neuronal cells |
| 07/11/2002 | WO2001021190A9 Treatment for narcolepsy |
| 07/11/2002 | WO2001020018A3 Diagnosing and treating arthritic disorders |
| 07/11/2002 | WO2001016322A3 Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes |
| 07/11/2002 | WO2001013927A9 Improved topical compositions containing probiotic bacteria, spores, and extracellular products and uses thereof |
| 07/11/2002 | WO2001011086A9 Methods of screening for angiogenesis modulators |
| 07/11/2002 | WO2001010454B1 Pharmaceutical composition comprising peg-asparaginase for the treatment of hiv infection |
| 07/11/2002 | WO2000073321A9 Human tumor necrosis factor receptor tr10 |
| 07/11/2002 | WO2000072834A3 Agent for expression of long-term potentiation of synaptic transmission comprising compound having brain somatostatin activation property |
| 07/11/2002 | WO2000067016A9 Methods for the identification of compounds for the treatment of alzheimer's disease |
| 07/11/2002 | WO2000063438A3 Method of classifying a thyroid carcinoma using differential gene expression |
| 07/11/2002 | WO2000062067A9 Novel transduction molecules and methods for using same |
| 07/11/2002 | WO2000061231A3 Medical use |
| 07/11/2002 | WO2000058472A9 Isolated dna encoding cullin regulators roc1 and roc2, isolated proteins encoded by the same, and methods utilizing the same |
| 07/11/2002 | WO2000056376A9 Medical devices and applications of polyhydroxyalkanoate polymers |
| 07/11/2002 | WO2000049937A9 Trpm-2 antisense therapy |
| 07/11/2002 | US20020091249 Human tumor suppressor polypeptides |
| 07/11/2002 | US20020091244 Nucleotide sequences for use in diagnosis and treatment of cancer and immunological disorders |
| 07/11/2002 | US20020091236 Nucleotide sequences coding preferential polypeptide for use in detection of bactericides |
| 07/11/2002 | US20020091230 Made from a bis/gamma-hydroxyhydrocarbyl/ ester of terephthalic acid and a phosphorodichloridate; biocompatible before and upon biodegradation |
| 07/11/2002 | US20020091160 Administering orally a source of at least one of L-arginine and L-lysine as other than a natural food source |
| 07/11/2002 | US20020091157 Cyclic GMP (cGMP)-specific phosphodiesterase (PDE) inhibitor (e.g., exisulind) to reduce the side effects or increase the efficacy of treatment with an antineoplastic platinum coordination complex like cisplatin or carboplatin. |
| 07/11/2002 | US20020091156 Novel arginine/ascorbic acid mixed powder as an oral supplement |
| 07/11/2002 | US20020091149 Combination of the macrocyclic lactone moxidectin and an phenyl-substituted 4-cyano-3-halo-2-(trifluoromethyl)pyrrole compound. |
| 07/11/2002 | US20020091145 Behavior chemotherapy |
| 07/11/2002 | US20020091140 Method of treating and preventing migraine headaches |